Clinical Trial

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-19; most recent amendment 2025-04-24.
Status change: Not Yet Recruiting → Recruiting 2024-02-04
Trial Details
NCT Number NCT06188624
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Advanced Cancer
Enrollment 150 participants
Start Date 2024-02-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-25